Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Travere Therapeutics, Inc. - Common Stock
(NQ:
TVTX
)
29.30
+1.43 (+5.13%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Today 16:01 EST
From
Travere Therapeutics, Inc.
Via
Business Wire
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
↗
February 17, 2026
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million
↗
February 17, 2026
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.
Via
The Motley Fool
Topics
Regulatory Compliance
Why Did TVTX Stock Crash 30% In Pre-Market Today?
↗
January 13, 2026
Via
Stocktwits
Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Technical and Fundamental Momentum for Growth Investors
↗
January 05, 2026
Via
Chartmill
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake
↗
February 17, 2026
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.
Via
The Motley Fool
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More
↗
February 17, 2026
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.
Via
The Motley Fool
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
February 12, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 11, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
February 04, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?
↗
January 25, 2026
This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.
Via
The Motley Fool
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?
↗
January 24, 2026
This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.
Via
The Motley Fool
TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
January 16, 2026
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Why Travere Therapeutics Stock Got Trounced on Tuesday
↗
January 13, 2026
A regulatory decision on a top investigational drug won't be coming as soon as hoped.
Via
The Motley Fool
Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS
January 13, 2026
On January 13, 2026, Travere Therapeutics (NASDAQ: TVTX) faced a sharp reversal of fortune as the U.S. Food and Drug Administration (FDA) announced a three-month extension for its review of Filspari...
Via
MarketMinute
Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April
↗
January 13, 2026
According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved.
Via
Stocktwits
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
January 13, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Let's have a look at the top gainers and losers in the middle of the day of today's session.
↗
January 13, 2026
Via
Chartmill
These stocks are gapping in today's session
↗
January 13, 2026
Via
Chartmill
These stocks that are showing activity before the opening bell on Tuesday.
↗
January 13, 2026
Via
Chartmill
Travere Therapeutics Provides Corporate Update and 2026 Outlook
January 12, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Travere Therapeutics, Inc.
Via
Business Wire
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday
↗
December 24, 2025
Two analysts waxed bullish on the future of the company.
Via
The Motley Fool
Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Momentum and Technical Setup for Growth Investors
↗
December 18, 2025
Travere Therapeutics (TVTX) shows strong earnings momentum, a bullish technical uptrend, and a current consolidation phase, presenting a potential breakout setup for growth investors.
Via
Chartmill
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 11, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Inc (NASDAQ:TVTX) Screened as a High Growth Momentum Stock with Strong Technical Setup
↗
November 27, 2025
Travere Therapeutics (TVTX) shows strong high-growth momentum with surging sales and a positive technical setup, signaling a potential breakout.
Via
Chartmill
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year
↗
November 18, 2025
Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.
Via
Investor's Business Daily
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why
↗
November 18, 2025
A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year.
Via
The Motley Fool
Topics
Regulatory Compliance
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally
↗
November 18, 2025
A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.
Via
The Motley Fool
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
